non-infectious anterior uveitisTrials & approvals
Roivant Sciences' Brepocitinib demonstrates significant efficacy in Phase 3 trials for non-infectious uveitis, meeting all primary and secondary endpoints. Analysts suggest it may outperform Humira, indicating strong potential in the inflammatory eye disease market.
Brepocitinib is on a roll. After winning approval for an autoimmune skin disease, Roivant Sciences subsidiary Priovant’s drug hit all primary and secondary endpoints in a pair of Phase 3 non-infectious uveitis trials, leading analysts to say the candidate “looked superior to Humira.”
Original title: “Roivant's TYK2/JAK inhibitor reduces need for steroids in inflammatory eye disease”